95 related articles for article (PubMed ID: 21503888)
1. PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
Vincenzi B; Santini D; Perrone G; Graziano F; Loupakis F; Schiavon G; Frezza AM; Ruzzo AM; Rizzo S; Crucitti P; Galluzzo S; Zoccoli A; Rabitti C; Muda AO; Russo A; Falcone A; Tonini G
J Cell Physiol; 2012 Mar; 227(3):927-33. PubMed ID: 21503888
[TBL] [Abstract][Full Text] [Related]
2. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
3. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
4. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.
Sastre J; Aranda E; Massutí B; Tabernero J; Chaves M; Abad A; Carrato A; Reina JJ; Queralt B; Gómez-España A; González-Flores E; Rivera F; Losa F; García T; Sanchez-Rovira P; Maestu I; Díaz-Rubio E
Crit Rev Oncol Hematol; 2009 May; 70(2):134-44. PubMed ID: 19111473
[TBL] [Abstract][Full Text] [Related]
5. Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
Cassidy J
Clin Adv Hematol Oncol; 2008 May; 6(5):360-1. PubMed ID: 18516025
[No Abstract] [Full Text] [Related]
6. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655
[TBL] [Abstract][Full Text] [Related]
7. PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy.
Vincenzi B; Santini D; Schiavon G; Frezza AM; Silletta M; Crucitti P; Casali P; Dei Tos AP; Rossi S; Rizzo S; Badalamenti G; Tomasino RM; Russo A; Butrynski JE; Tonini G
J Cell Physiol; 2012 Apr; 227(4):1657-62. PubMed ID: 21678421
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Baraniskin A; Munding J; Schulmann K; Meier D; Porschen R; Arkenau HT; Graeven U; Schmiegel W; Tannapfel A; Reinacher-Schick A
Clin Colorectal Cancer; 2011 Mar; 10(1):24-9. PubMed ID: 21609932
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
[TBL] [Abstract][Full Text] [Related]
10. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
[TBL] [Abstract][Full Text] [Related]
12. Integrating oxaliplatin into the management of colorectal cancer.
Schmoll HJ; Cassidy J
Oncologist; 2001; 6 Suppl 4():24-8. PubMed ID: 11585971
[TBL] [Abstract][Full Text] [Related]
13. On 5-fluorouracil therapy of colorectal cancer.
Jensen SA
Dan Med J; 2013 Jul; 60(7):B4603. PubMed ID: 23809976
[No Abstract] [Full Text] [Related]
14. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
15. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
[TBL] [Abstract][Full Text] [Related]
16. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
18. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Folprecht G; Köhne CH
Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
[TBL] [Abstract][Full Text] [Related]
19. Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
Lee JH; Lee JH; Kim TW; Lee KH; Kang YK; Lee JS; Kim SH; Kim HC; Yu CS; Kim JC; Kim WK
J Korean Med Sci; 2001 Feb; 16(1):69-74. PubMed ID: 11289404
[TBL] [Abstract][Full Text] [Related]
20. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
Rasmussen MH; Jensen NF; Tarpgaard LS; Qvortrup C; Rømer MU; Stenvang J; Hansen TP; Christensen LL; Lindebjerg J; Hansen F; Jensen BV; Hansen TF; Pfeiffer P; Brünner N; Ørntoft TF; Andersen CL
Mol Oncol; 2013 Jun; 7(3):637-46. PubMed ID: 23506979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]